Corixa


Also found in: Dictionary, Wikipedia.
Related to Corixa: Corixidae
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for Corixa

type genus of the Corixidae: boat bugs

References in periodicals archive ?
Corixa issued a formal request for proposal in January as part of its competitive agency review process and selected three finalists to present their ideas and capabilities to Corixa's leaders in February.
Under the terms of the agreement, Corixa will provide Beaufour Ipsen with exclusive worldwide rights to develop and market its AnergiX.
The issued patents cover composition of matter and utility claims for antigens that Corixa believes may be useful in performing rapid diagnosis and potential prevention of babesia or HGE infection.
For the first quarter, Corixa reported total revenue of $13.
The patents stem from Corixa experimentation conducted and directed by Steven Reed, PhD, executive vice president and chief scientific officer of Corixa.
Corixa anticipates that the merger will occur later today, subject to the satisfaction or waiver of all other closing conditions to the merger.
This is the first milestone payment Corixa has received under the terms of a 1999 agreement with JT, which provides JT with certain rights to develop vaccine products containing Corixa's novel lung cancer antigens, including antigens formulated using Corixa's microsphere delivery system and proprietary adjuvant technologies.
Under the terms of the agreement, Corixa has option rights to exclusively develop and commercialize human antibody products created using the TC Mouse(TM) technology.
As a result, Corixa will conduct preclinical and clinical testing of a new candidate vaccine produced using M.
Corixa has previously sponsored clinical trials with Her-2/neu peptide vaccines and announced in October of 1998 the license of its these vaccines to SmithKline Beecham.
Corixa intends to contribute three targets initially and up to six or more targets a year during the term of the agreement.
Stanford Rook Holdings plc (London, England; 0171-637-0418) announced that its Group operating company SR Pharma has signed an exclusive license agreement with Corixa Corporation (Seattle, WA; 206-754-5720) that allows Corixa to exploit a new immunotherapeutic product for the treatment of Psoriasis, Diabetes, Multiple Sclerosis and Rheumatoid Arthritis.
Corixa Corporation (Nasdaq: CRXA), a research-based biotechnology company, today announced results for the fourth quarter and year ended December 31, 1999.